meloxicam

Pletcher To Begin Serving Suspension, Repole Reacts and Legal Team Vows to Fight On

According to the rulings page of the New York State Gaming Commission, trainer Todd Pletcher began serving a 10-day suspension Thursday. The suspension stems from the 2022 GI Hopeful Stakes when the Pletcher-trained Forte (Violence) tested positive for Meloxicam, a non-steroidal anti-inflammatory. Pletcher has denied using the medication with Forte. The Gaming Commission also ruled that Forte was officially disqualified from the Hopeful victory. The news from the Gaming Commission led owner Mike Repole to post a long and scathing tweet on X. "The New York State Gaming Commission @NYSGamingComm...

[ Read More ]
Hall of Fame trainer Todd Pletcher
Court Rules Against Pletcher in Forte Matter

The New York State Supreme Court, Appellate Division has ruled against trainer Todd Pletcher in his appeal of a 10-day suspension and $1,000 fine he received after Forte (Violence) tested positive for Meloxicam in the 2022 GI Hopeful Stakes. A separate matter, regarding whether or not Forte should be disqualified, is still pending. It was not immediately clear whether or not Pletcher would have to begin serving his suspension. In May of 2023, it was announced that Forte had tested positive for what is a nonsteroidal anti-inflammatory medication. Pletcher issued...

[ Read More ]
Three Lingering NY Drug Positives as Testing Transfers to HISA

On the day that Thoroughbred drug testing nationwide got transferred to the control of the Horse Racing Integrity and Safety Act (HISA) Authority, Robert Williams, the executive director for the New York State Gaming Commission (NYSGC), disclosed during that board's monthly meeting that three outstanding Thoroughbred drug positives remain unadjudicated by the commission and are still lingering at various stages in the regulatory process. That disclosure is not only timely because of the HISA Authority's May 22 implementation of the Anti-Doping and Medication Control program. Monday's news of the three...

[ Read More ]
X

Never miss another story from the TDN

Click Here to sign up for a free subscription.